home / stock / nrx:cc / nrx:cc news

NRX:CC News and Press, NurExone Biologic Inc. From 01/13/23

Stock Information
Company Name: NurExone Biologic Inc.
Stock Symbol: NRX:CC
Market: TSXVC
Website: nurexone.com
Menu
NRX:CC NRX:CC Quote NRX:CC Short NRX:CC News NRX:CC Articles NRX:CC Message Board
Get NRX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
NRX:CC - United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone

HAIFA, Israel and CALGARY, Alberta, Jan. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CVE) (J90:FRA) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with tra...
NRX:CC - United States Patent Office Allows Patent to Exosome Biomedical Company NurExone

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System disease Haifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company devel...

NRX:CC - NurExone Issues Annual Shareholder Letter

Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased...

NRX:CC - NurExone Announces Completion of Securites for Debt Settlement

Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is a...
NRX:CC - Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error....

NRX:CC - NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company de...

NRX:CC - NurExone Announces Securities for Debt Settlement

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announci...
NRX:CC - NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate...

NRX:CC - NurExone Announces Completion of Securities for Debt Settlements

Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, i...

NRX:CC - NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration

The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meeting A pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into t...
Previous 10 Next 10